Faron Pharmaceuticals Oy
Company Profile
Business description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Contact
Joukahaisenkatu 6 B
Turku20520
FINT: +358 24695151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.60 | 25.40 | -0.29% |
| CAC 40 | 7,684.68 | 80.43 | -1.04% |
| DAX 40 | 23,516.23 | 255.22 | -1.07% |
| Dow JONES (US) | 42,197.79 | 769.83 | -1.79% |
| FTSE 100 | 8,850.63 | 34.29 | -0.39% |
| HKSE | 23,892.56 | 142.82 | -0.59% |
| NASDAQ | 19,406.83 | 255.66 | -1.30% |
| Nikkei 225 | 37,834.25 | 338.84 | -0.89% |
| NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
| S&P 500 | 5,976.97 | 68.29 | -1.13% |
| S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
| SSE Composite Index | 3,377.00 | 25.66 | -0.75% |